Are you Dr. Josephson?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
921 Terry Ave
Seattle, WA 98104Phone+1 206-292-6570Fax+1 206-520-5620
Summary
- Dr. Neil Josephson, MD is an oncologist in Seattle, Washington. He is currently licensed to practice medicine in Washington, Oregon, and Illinois. He is an Associate Professor at University of Washington School of Medicine.
Education & Training
Columbia University Vagelos College of Physicians and SurgeonsClass of 1988
Certifications & Licensure
OR State Medical License 1991 - Present
WA State Medical License 1994 - 2025
IL State Medical License 1988 - 1993
Publications & Presentations
PubMed
- 11 citationsResults of genetic analysis of 11 341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States.Jill M Johnsen, Shelley N Fletcher, Angela Dove, Haley McCracken, Beth K Martin
Journal of Thrombosis and Haemostasis. 2022-09-01 - 104 citationsBAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expressionBarbara A. Konkle, Christopher E. Walsh, Miguel A. Escobar, Neil C. Josephson, Guy Young
Blood. 2021-02-11 - 26 citationsThree‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphomaAnn S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura
British Journal of Haematology. 2020-02-12
Press Mentions
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract CancerApril 28th, 2022- Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast CancerDecember 8th, 2021
- Zymeworks Announces Abstract for Zanidatamab in First-Line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual CongressSeptember 12th, 2021
- Join now to see all
